Three known different genetic variants of the hepatocarcinoma component were used to assess the assay sensitivity: ABL1 intronic g.164164 G>T (variant frequency hepatocarcinoma = 24% sarcoma = 0%), PIK3CA H1047R (variant frequency hepatocarcinoma = 28% sarcoma = 0%) and TP53 F109C (variant frequency hepatocarcinoma = 87%; sarcoma = 55%). Here, TP53 is linked to sarcoma.